Last Updated: 27/02/2025
A vaccine for malaria: An Australian concept and development strategy
Objectives
This project will focus on the pre-clinical development of a world-first whole parasite blood-stage malaria vaccine.
Malaria results in >200 million cases and 450,000 deaths/yr. With existing control measures becoming increasingly less effective, the development of an effective malaria vaccine is critical. A single sub-unit malaria vaccine has been licensed; however it provides moderate, short term protection only. By including blood-stage proteins from the whole parasite formulated within novel liposomes to optimise immunogenicity and enable development of a cryopreserved (field deployable) vaccine formulation, our vaccine will be game-changing. This project will focus on three activities pertaining to the development of a field-deployable P. falciparum whole parasite blood-stage malaria vaccine: further optimisation of the vaccine formulation and vaccination regimen in pre-clinical models of malaria, vaccine stability studies and establishment of critical GMP-compliant manufacturing processes and GMP-grade reagents for future clinical vaccine development.
Jun 2019 — Dec 2022
$354,176
Related Resources
